# SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

> **NCT05022654** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sichuan Baili Pharmaceutical Co., Ltd.** · enrollment: 22 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinomas

## Interventions

- **DRUG:** SI-B001
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT05022654
- **Lead sponsor:** Sichuan Baili Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-13
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05022654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05022654, "SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05022654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*